title: Long-term therapy with nucleoside/nucleotide analogues for chronic hepatitis B in Asian patients.
abstract: Of the estimated 400 million patients with chronic hepatitis B (CHB) globally, approximately 75% are Asians, representing a clinically important subgroup with a higher risk of cirrhosis and hepatocellular carcinoma than Caucasian patients. This review summarizes recent data from clinical long-term and real-life studies of entecavir and tenofovir, the recommended first-line oral therapies for treating CHB, in nucleoside/nucleotide-naive Asian CHB patients with compensated or decompensated liver disease. Long-term treatment with entecavir or tenofovir achieved profound and durable virological suppression, and led to improved liver histology and function. The data presented in this review will help physicians in making evidence-based decision choices regarding first-line antiviral therapy and long-term management in Asian CHB patients.
authors.affiliation: Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY, USA. Cpan11355@yahoo.com.
authors.forename: Calvin Q
authors.initials: CQ
authors.lastname: Pan
authors.forename: Ke-Qin
authors.initials: KQ
authors.lastname: Hu
authors.forename: Naoky
authors.initials: N
authors.lastname: Tsai
mesh_terms: D000225:Adenine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D000998:Antiviral Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D044466:Asian People; D006528:Carcinoma, Hepatocellular / Q000209:etiology / Q000517:prevention & control; D018450:Disease Progression; D024882:Drug Resistance, Viral; D006147:Guanine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D006515:Hepatitis B virus; D019694:Hepatitis B, Chronic / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D008113:Liver Neoplasms / Q000209:etiology / Q000517:prevention & control; D063065:Organophosphonates / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000068698:Tenofovir; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D063065:Organophosphonates; C413685:entecavir; D006147:Guanine; D000068698:Tenofovir; D000225:Adenine